Dear client

The coronavirus disease (COVID-19) outbreak causes operational and organisational challenges which we will need to solve for our company. This may impact you and your business. We would therefore like to inform you on how we are planning to meet these challenges during the disease outbreak.

We are available

In Mericon we have now implemented social distance measures for our staff, encouraging remote work from home when feasible. This also means that we will cancel all non-essential work travel, and the contact with our clients will be maintained through online channels like Teams/Skype and telephone, as well as email.

We will therefore be available to deliver our services as close as possible to a normal situation.

As your vendor, we will do our very best to ensure that all services will be provided as agreed. In case this should not be possible, we will get in touch as soon as possible.

We are adapting to the national restrictions and guidelines

The times ahead will certainly be challenging, and Mericon will of course adapt to the national measures to help preventing the transmission of COVID-19. At the same time, we will try to maintain business as usual as far as possible.

We will provide updated information in case our routines are changed.

Best regards,

Nils-Ragnar Myhra

Managing Director Mericon AS


Grenland makes an effort towards building up Drug Industry in the region - Vekst I Grenland (Invest in Grenland, ViG) has in collaboration with Skien municipality, Kragerø municipality, Vekst I Grenland and the project Helseinnovasjon (Health Innovation) Telemark initiated a project with the… Read more
Coronavirus disease - The Norwegian Institute of Public Health has made a topic page which includes updated advice and information about the new coronavirus disease COVID-19, and the situation i Norway. https://www.fhi.no/en/id/infectious-diseases/coronavirus/ Read more
Need of medicinal products in Norway - The Norwegian Medicines Agency has recently announced a need for more suppliers or alternatives on the market in Norway for the active substances glyceryl trinitrate, ivermectin, erythromycin and Ferrous (II)… Read more